Nektar Therapeutics chief R&D officer Zalevsky sells $13,388 in shares

Jonathan Zalevsky, the chief R&D officer at Nektar Therapeutics, sold 186 shares of the company's common stock on August 18, 2026, for a total of $13,388. The sale took place at prices ranging from $71.78 to $72.49, with an average cost of $71.98 per share. Since the transaction, the stock has appreciated to $74.53, marking a significant 166% increase over the past year.

The sale was made to satisfy tax obligations due to the vesting of restricted stock units (RSUs) that Mr. Zalevsky holds, indicating that the transaction was not a discretionary trade. After the sale, Mr. Zalevsky still owns 9,570 shares of Nektar Therapeutics common stock.

InvestingPro analysis suggests that the stock may be overvalued based on its Fair Value assessment. The company maintains a higher cash position than debt on its balance sheet, yet it remains unprofitable. For investors seeking more detailed insights, a Pro Research Report on NKTR is available, which is part of a collection of 1,400+ US equities analyses.

Recently, Nektar Therapeutics issued its second-quarter financial results, revealing a loss of $1.23 per share, which was better than the estimated $2.00 per share loss. However, the company's revenue fell short of expectations, with $10.13 million reported against the projected $10.38 million. Despite this, Nektar reassured investors that its cash reserves are sufficient to fund clinical development until 2028.

These recent events are part of Nektar Therapeutics' ongoing path toward commercialization. Notably, the stock experienced a drop in after-hours trading following the earnings release, underscoring the mixed signals in the company's financial and operational trajectory. This account, while based on factual information, was crafted solely through AI assistance and reviewed by an editor to ensure accuracy. For additional context, the company's T&C applies.